Granules India Limited (NSE:GRANULES)
439.55
-10.45 (-2.32%)
Aug 8, 2025, 3:29 PM IST
Granules India Revenue
In the fiscal year ending March 31, 2025, Granules India had annual revenue of 44.82B INR, down -0.55%. Granules India had revenue of 11.97B in the quarter ending March 31, 2025, with 1.84% growth.
Revenue
44.82B
Revenue Growth
-0.55%
P/S Ratio
2.38
Revenue / Employee
11.02M
Employees
4,066
Market Cap
106.68B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 44.82B | -247.59M | -0.55% |
Mar 31, 2024 | 45.06B | -55.50M | -0.12% |
Mar 31, 2023 | 45.12B | 7.47B | 19.84% |
Mar 31, 2022 | 37.65B | 5.27B | 16.29% |
Mar 31, 2021 | 32.38B | 6.39B | 24.59% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Mankind Pharma | 129.10B |
Apollo Hospitals Enterprise | 217.94B |
Zydus Lifesciences | 232.42B |
Fortis Healthcare | 77.86B |
Aurobindo Pharma | 320.25B |
Granules India News
- 7 days ago - Granules India’s Hyderabad unit receives one US FDA observation after Pre-Approval Inspection - Business Upturn
- 22 days ago - Granules India CEO Kandiraju Venkata Sitaram Rao resigns, effective July 31 - Business Upturn
- 6 weeks ago - Granules India clears US FDA Pre-Approval Inspection with zero observations - Business Upturn
- 7 weeks ago - Granules India’s Bonthapally facility completes US FDA inspection with one observation - Business Upturn
- 7 weeks ago - Pharma scrips fall on Trump tariff threat - The Times of India
- 5 months ago - Granules India shares drop nearly 3% amid US FDA warning letter - Business Upturn
- 5 months ago - Granules India shares drop 3.6% after receiving US FDA warning letter for Gagillapur facility - Business Upturn
- 5 months ago - Top Stocks in News Today, Friday, February 28: GE Power, Coal India, Sanofi, Granules India, RVNL, Transrail Lighting, TATA Motors and more - Business Upturn